Trial Profile

Prospective Registry of Iclusig (Ponatinib) Used in Clinical Practice for the Treatment of Patients With Chronic Myeloid Leukemia or Ph+ Acute Lymphoblastic Leukemia in Belgium

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 16 Aug 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ponatinib (Primary)
Indications Chronic myeloid leukaemia; Precursor cell lymphoblastic leukaemia-lymphoma
Focus Therapeutic Use
Sponsors Incyte Biosciences International

Most Recent Events

17 Jun 2022 Interim Results (n=77) of 5-year-Belgian registry data on ponatinib use in CML and Ph+ALL patients, presented at the 27th Congress of the European Haematology Association
11 Apr 2022 Status changed from recruiting to completed.
01 Jul 2021 Results (n = 50) assessing first report of prospective data of patients with CML or Ph+ ALL treated with ponatinib in routine clinical practice, published in the Annals of Hematology

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com